We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Roche is finally throwing in the towel on crenezumab, the antiamyloid antibody researchers hoped might prevent the disease in a group of South American families genetically destined to develop it at a very young age. Read More
Acadia is having another go at Nuplazid (pimavanserin), hoping to convince the FDA’s Psychopharmacologic Drugs Advisory Committee that the antipsychotic should win a new indication as a treatment for dementia-related hallucinations and delusions. Read More
As global cases of monkeypox continue to increase, the World Health Organization (WHO) is recommending two smallpox vaccines for off-label use against monkeypox and one that has been approved for prevention of monkeypox. Read More
The Supreme Court unanimously ruled that the Department of Health and Human Services (HHS) can’t reduce its payment rates for only a certain group of hospitals — namely, 340B Drug Discount Program hospitals — without first conducting a survey of hospitals’ acquisition costs for each covered outpatient drug. Read More
Due to a very low rate of hospitalization or death observed in the standard-risk patient population, Pfizer has decided to end enrollment in the study. Read More
“After more than a decade of price increases in seemingly coordinated fashion, a month’s supply is priced at $529 for Eliquis and $516 for Xarelto,” they said. Read More
An annual report from the FDA’s Center for Drug Evaluation and Research (CDER) says the agency’s drug manufacturing inspection activities fell short of CDER’s self-determined goals in fiscal year 2021, primarily due to COVID-related restrictions. Read More
Amylyx’s potentially pricey amyotrophic lateral sclerosis (ALS) drug AMX0035 can only be cost-effective if it costs no more than $18,200 per year — much less than Radicava, the only approved ALS drug, which ticks in at $171,000 per year. Read More